Moderna, Inc. Operating Lease Cost
Moderna, Inc. (MRNA) reported Operating Lease Cost of $89.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-20
- Moderna, Inc. operating lease, cost for the quarter ending 2020-12-31 was $4.02M, a 25.51% decline year-over-year.
- Moderna, Inc. operating lease, cost for the quarter ending 2020-09-30 was $3.96M, a 2.32% increase year-over-year.
- Moderna, Inc. operating lease, cost for the quarter ending 2020-06-30 was $4.38M, a 13.09% increase year-over-year.
- Moderna, Inc. operating lease, cost for the quarter ending 2020-03-31 was $4.64M, a 19.79% increase year-over-year.
- Moderna, Inc. operating lease, cost for fiscal 2025 was $89.00M, a 13.59% decline from fiscal 2024.
- Moderna, Inc. operating lease, cost for fiscal 2024 was $103.00M, a 17.05% increase from fiscal 2023.
- Moderna, Inc. operating lease, cost for fiscal 2023 was $88.00M, a 83.33% increase from fiscal 2022.
- Moderna, Inc. operating lease, cost for fiscal 2022 was $48.00M, a 100.00% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $89.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $103.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $88.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $48.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $24.00M 10-K · filed 2024-02-23 | ||||
| 2020-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $7.99M derived: sum of 2 quarters · filed 2023-02-24 | $12.36M derived: sum of 3 quarters · filed 2023-02-24 | $17.00M 10-K · filed 2023-02-24 | $16.94M 10-K · filed 2021-02-26 |
| 2020-09-30 | $3.96M 10-Q · filed 2020-10-30 | $8.34M derived: sum of 2 quarters · filed 2020-10-30 | $12.98M 10-Q · filed 2020-10-30 | $18.38M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-06-30 | $4.38M 10-Q · filed 2020-08-06 | $9.02M 10-Q · filed 2020-08-06 | $14.42M derived: sum of 3 quarters · filed 2021-02-26 | $18.29M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-03-31 | $4.64M 10-Q · filed 2020-05-07 | $10.04M derived: sum of 2 quarters · filed 2021-02-26 | $13.91M derived: sum of 3 quarters · filed 2021-02-26 | $17.78M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $9.27M derived: sum of 2 quarters · filed 2021-02-26 | $13.14M derived: sum of 3 quarters · filed 2021-02-26 | $17.02M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $3.87M 10-Q · filed 2020-10-30 | $7.74M derived: sum of 2 quarters · filed 2020-10-30 | $11.61M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $3.87M 10-Q · filed 2020-08-06 | $7.74M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $3.87M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |